Nektar Therapeutics (FRA:ITH)
€ 1.268 -0.003 (-0.24%) Market Cap: 240.14 Mil Enterprise Value: 79.17 Mil PE Ratio: 0 PB Ratio: 2.03 GF Score: 48/100

Nektar Therapeutics at Cowen Health Care Conference Transcript

Mar 12, 2019 / 01:20PM GMT
Release Date Price: €31.07 (+0.94%)
Chris Shibutani;Jonathan Zalevsky
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning, let's get started. My name is Chris Shibutani, I'm a member of the Cowen Equity Research team of the biotech group. I'm very pleased to have Nektar Therapeutics present with us once again. Yesterday, for those of you who attended our panel on the novel I-O therapeutics, we had few of the world's leading experts Jason Luke, Chuck Drake comment as well as accompanying with the KOL survey's about, a, the significant unmet need that still exists and the vast array of opportunities that are out there. Nothing is simple, and there's no single solution. And therefore, I think having an approach that embraces that complexity, the classic multiple shots on goal and breadth of assets, I think, will be essential as we tackle so many of these dimensions. A company that is very well-positioned to continue to unveil assets and approach strategies to address these needs, Nektar therapeutics here to update us. Jonathan Zalevsky, Chief Scientific Officer, correct? Thanks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot